Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895
TL-895 is an investigational second-generation BTK inhibitor for the treatment of B-cell malignancies. We found that TL-895 undergoes hepatocellular uptake by OATP1B-type transporters in advance of extensive CYP3A-mediated metabolism but is unlikely to perpetrate pharmacokinetic DDIs that could compromise drug safety in the context of polypharmacy regimens.
Authors
- Mahesh R. Nepal (ORCID: https://orcid.org/0000-0001-7259-2699)
- Kevin M. Huang (ORCID: https://orcid.org/0000-0001-6561-3295)
- Eman Abd El-Mordy Elsayed Ahmed (ORCID: https://orcid.org/0000-0003-0973-2630)
- Thomas Drabison
- Daelynn R. Buelow (ORCID: https://orcid.org/0000-0002-4413-5711)
- Shelley Orwick (ORCID: https://orcid.org/0000-0002-4537-1409)
- Jack C. Stromatt (ORCID: https://orcid.org/0000-0001-8864-4617)
- Alex Sparreboom (ORCID: https://orcid.org/0000-0003-2660-6644)
- Eric D. Eisenmann (ORCID: https://orcid.org/0000-0003-1176-675X)
- Sharyn D. Baker (ORCID: https://orcid.org/0000-0003-3062-3252)
- Anika T. Chowdhury
Institutions
- The Ohio State University (US)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-08-22
- DOI
- https://doi.org/10.1158/2767-9764.crc-25-0265
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- Pelotonia
- National Institutes of Health